Member Info for oxygen

Yes surprised they opted for $85 as their benchmark, if tensions in the ME subside during H2 & Opec decide they’ll turn the taps back on, then it’s back to what their Hedging Strategy looks like.

Why the rush,Q3 EWT is still months away ….

Expect a flurry of new Contract awards over the coming months given global investment in the O&G sector ( outside of the NS …,thanks to Hunt ) has its own momentum, and PFC’s own comments “ a healthy Group pipeline scheduled for award in the next 18 months of US$62 billion “. We also have a healthy level of Traders “ Short”.

Yes pleased with all that, have moved AV. up in my Portfolio no longer in the Boring Category !

Brent needs to get moving higher given “FCF is only expected to be marginally positive in 2024 assuming $85/bbl Brent” !

Annoying, but fairly academic with every likelihood Labour will shortly be in Government who most probably will just have a straight 78% Profits Tax, which won’t be that much of a shock. It’s the Investment Allowance next on the agenda that concerns me more !

Best just accept that as investors here we are all just as ‘thick as mince’ and the Market is always right. Hopefully it may just curb the incessant guessing which is nearly always wrong.

Haven’t been paying attention here, but that’s a welcome release of funds. Still believe this has a good way to go under the current CEO.

Think you’l find AS said previously "I believe that we are on the verge of a paradigm shift “….so not there yet, nowt wrong with that if you read his messaging correctly !

Well according to AS you’ll need to await” Phase 2 efficacy study(subject to FDA approval) which the Board considers to be a major value-driving event for the Group “. But there again such value driving events in the past have driven us down to this point !

Well if no TR1’s there is a good chance they’ve already allocated their holdings to cover a few Short positions. Institutions don’t do loyalty, unless you’re generating FCF & Dividend returns, we were likely seen as chance to generate a quick return and who can blame them. AS isn’t the only one who can tell a good story !

Problem with scientists they thrive on trying to push boundaries with their inventions. That’s fine when they play with their own money, but living on others means comes with a responsibility to protect that support, and not be taken for granted.

I’ll sit it out, may add in the coming weeks if it falls below the Placing price as can’t see what will drive this higher in the short term. Not selling thou as somewhat of a financial masochiste.

Problem for AS is that they’re not always in control of timelines, the FDA in particular are fairly stringent and methodical in their approach and can easily knock you back a few months if not careful, hence the liberal use of the word ‘ expected’.

Again merely highlighting why trust in this Company has evaporated, previous statements never seem to be corrected once facts change !

Be interesting to see the REX take up, which will indicate where the Retail investors see this Share going over the next few months. With management credibility shot it wouldn’t surprise to see it fall rather flat.

I’m coming to believe that we are seeing the influence of Christina Coughlin here, she won’t allow the messaging to get in front of itself, she has a highly regarded reputation for good reason. The real question though is what, if anything, she is also seeing in the data readout !

My guess is most of those are sells by the much lauded Institutional Investors that show little interest staying around and happy to have made a fast buck, for them loyalty is for others, AS should take note !

In the secondary market retail shareholders are so far down the pecking order we count for little, thus Directors probably feel we’re very ungrateful in not recognising a Retail Offer, of sorts, was indeed made and we need to accept our place in life !

Just been reading an article on Nikola Tesla, a brilliant scientist but lousy financier so died penniless, I’ll email AS a copy.